ENTA
Enanta Pharmaceuticals Inc
NASDAQ: ENTA · HEALTHCARE · BIOTECHNOLOGY
$11.55
-5.17% today
Updated 2026-10-28
Market cap
$329.41M
P/E ratio
—
P/S ratio
5.05x
EPS (TTM)
$-2.42
Dividend yield
—
52W range
$10 – $17
Volume
0.3M
Enanta Pharmaceuticals Inc (ENTA) Insider transactions
Net insider activity
Net buying (2,065,420 shares)
Buy transactions
54
Sell transactions
46
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-08-08 | ROTTINGHAUS, SCOTT T. | Chief Medical Officer | Sale | 1,467 | $13.34 | $19569.78 |
| 2026-03-11 | VANCE, TERRY | Director | Buy | 20,000 | — | — |
| 2026-03-11 | RUSSELL, LESLEY | Director | Buy | 20,000 | — | — |
| 2026-03-11 | PETERSON, KRISTINE | Director | Buy | 20,000 | — | — |
| 2026-03-11 | HATA, YUJIRO S | Director | Buy | 20,000 | — | — |
| 2026-03-11 | FOLETTA, MARK G | Director | Buy | 20,000 | — | — |
| 2026-03-11 | CARTER, BRUCE L A | Director | Buy | 20,000 | — | — |
| 2026-02-12 | ROTTINGHAUS, SCOTT T. | Chief Medical Officer | Buy | 5,225 | — | — |
| 2026-02-12 | ROTTINGHAUS, SCOTT T. | Chief Medical Officer | Sale | 3,413 | $14.25 | $48635.25 |
| 2026-02-12 | ROTTINGHAUS, SCOTT T. | Chief Medical Officer | Buy | 1,650 | — | — |
| 2026-02-12 | OR, YAT SUN | Chief Scientific Officer | Buy | 5,225 | — | — |
| 2026-02-12 | OR, YAT SUN | Chief Scientific Officer | Sale | 3,413 | $14.25 | $48635.25 |
| 2026-02-12 | OR, YAT SUN | Chief Scientific Officer | Buy | 1,650 | — | — |
| 2026-02-12 | LUU, BRENDAN | Chief Business Officer | Buy | 4,987 | — | — |
| 2026-02-12 | LUU, BRENDAN | Chief Business Officer | Sale | 3,257 | $14.25 | $46412.25 |
| 2026-02-12 | LUU, BRENDAN | Chief Business Officer | Buy | 1,575 | — | — |
| 2026-02-12 | LULY, JAY R. | Director, President and CEO | Buy | 15,200 | — | — |
| 2026-02-12 | LULY, JAY R. | Director, President and CEO | Sale | 6,155 | $14.25 | $87708.75 |
| 2026-02-12 | LULY, JAY R. | Director, President and CEO | Buy | 4,800 | — | — |
| 2026-02-12 | KOWALSKY, MATTHEW PAUL | Chief Legal Officer | Buy | 4,175 | — | — |
| 2026-02-12 | KOWALSKY, MATTHEW PAUL | Chief Legal Officer | Sale | 1,902 | $14.25 | $27103.50 |
| 2026-02-12 | KOWALSKY, MATTHEW PAUL | Chief Legal Officer | Buy | 1,318 | — | — |
| 2026-02-12 | KIEFFER, TARA LYNN | Chief Product Strategy Officer | Buy | 4,987 | — | — |
| 2026-02-12 | KIEFFER, TARA LYNN | Chief Product Strategy Officer | Sale | 3,257 | $14.25 | $46412.25 |
| 2026-02-12 | KIEFFER, TARA LYNN | Chief Product Strategy Officer | Buy | 1,575 | — | — |
| 2025-12-05 | TROUT, HARRY R. III | See Remarks | Sale | 542 | $14.23 | $7712.66 |
| 2025-12-05 | ROTTINGHAUS, SCOTT T. | Chief Medical Officer | Sale | 798 | $14.23 | $11355.54 |
| 2025-12-05 | OR, YAT SUN | Chief Scientific Officer | Sale | 2,390 | $14.23 | $34009.70 |
| 2025-12-05 | LUU, BRENDAN | Chief Business Officer | Sale | 1,394 | $14.23 | $19836.62 |
| 2025-12-05 | LULY, JAY R. | Director, President and CEO | Sale | 4,743 | $14.23 | $67492.89 |
| 2025-12-05 | KIEFFER, TARA LYNN | Chief Product Strategy Officer | Sale | 2,106 | $14.23 | $29968.38 |
| 2025-12-05 | CAPPS, KATHLEEN S. | See Remarks | Sale | 323 | $14.23 | $4596.29 |
| 2025-12-02 | TROUT, HARRY R. III | See Remarks | Sale | 380 | $13.96 | $5304.80 |
| 2025-12-02 | CAPPS, KATHLEEN S. | See Remarks | Sale | 207 | $13.96 | $2889.72 |
| 2025-12-01 | TROUT, HARRY R. III | See Remarks | Sale | 105 | $14.12 | $1482.60 |
| 2025-12-01 | OR, YAT SUN | Chief Scientific Officer | Sale | 753 | $14.12 | $10632.36 |
| 2025-12-01 | LUU, BRENDAN | Chief Business Officer | Sale | 498 | $14.12 | $7031.76 |
| 2025-12-01 | LULY, JAY R. | Director, President and CEO | Sale | 1,885 | $14.12 | $26616.20 |
| 2025-12-01 | KIEFFER, TARA LYNN | Chief Product Strategy Officer | Sale | 753 | $14.12 | $10632.36 |
| 2025-12-01 | CAPPS, KATHLEEN S. | See Remarks | Sale | 85 | $14.12 | $1200.20 |
| 2025-11-25 | TROUT, HARRY R. III | See Remarks | Buy | 12,925 | — | — |
| 2025-11-25 | TROUT, HARRY R. III | See Remarks | Buy | 6,463 | — | — |
| 2025-11-25 | ROTTINGHAUS, SCOTT T. | Chief Medical Officer | Buy | 110,000 | — | — |
| 2025-11-25 | OR, YAT SUN | Chief Scientific Officer | Buy | 110,000 | — | — |
| 2025-11-25 | LUU, BRENDAN | Chief Business Officer | Buy | 90,000 | — | — |
| 2025-11-25 | LULY, JAY R. | Director, President and CEO | Buy | 310,000 | — | — |
| 2025-11-25 | KOWALSKY, MATTHEW PAUL | Chief Legal Officer | Buy | 90,000 | — | — |
| 2025-11-25 | KIEFFER, TARA LYNN | Chief Product Strategy Officer | Buy | 100,000 | — | — |
| 2025-11-25 | CAPPS, KATHLEEN S. | See Remarks | Buy | 6,325 | — | — |
| 2025-11-25 | CAPPS, KATHLEEN S. | See Remarks | Buy | 3,163 | — | — |
| 2025-08-08 | ROTTINGHAUS, SCOTT T. | Chief Medical Officer | Sale | 2,217 | $6.99 | $15496.83 |
| 2025-03-13 | VANCE, TERRY | Director | Buy | 15,700 | — | — |
| 2025-03-13 | RUSSELL, LESLEY | Director | Buy | 15,700 | — | — |
| 2025-03-13 | PETERSON, KRISTINE | Director | Buy | 15,700 | — | — |
| 2025-03-13 | HATA, YUJIRO S | Director | Buy | 15,700 | — | — |
| 2025-03-13 | FOLETTA, MARK G | Director | Buy | 15,700 | — | — |
| 2025-03-13 | CARTER, BRUCE L A | Director | Buy | 15,700 | — | — |
| 2025-02-12 | ROTTINGHAUS, SCOTT T. | Chief Medical Officer | Buy | 9,750 | — | — |
| 2025-02-12 | ROTTINGHAUS, SCOTT T. | Chief Medical Officer | Sale | 2,861 | $5.59 | $15992.99 |
| 2025-02-12 | OR, YAT SUN | Chief Scientific Officer | Buy | 9,750 | — | — |
| 2025-02-12 | OR, YAT SUN | Chief Scientific Officer | Sale | 4,324 | $5.59 | $24171.16 |
| 2025-02-12 | MELLETT, PAUL J | Chief Fin. & Admin Officer | Buy | 7,500 | — | — |
| 2025-02-12 | MELLETT, PAUL J | Chief Fin. & Admin Officer | Sale | 3,326 | $5.59 | $18592.34 |
| 2025-02-12 | LUU, BRENDAN | Chief Business Officer | Buy | 7,500 | — | — |
| 2025-02-12 | LUU, BRENDAN | Chief Business Officer | Sale | 3,326 | $5.59 | $18592.34 |
| 2025-02-12 | LULY, JAY R. | Director, President and CEO | Buy | 45,000 | $5.69 | $256050.00 |
| 2025-02-12 | LULY, JAY R. | Director, President and CEO | Buy | 25,500 | — | — |
| 2025-02-12 | LULY, JAY R. | Director, President and CEO | Sale | 7,484 | $5.59 | $41835.56 |
| 2025-02-12 | KIEFFER, TARA LYNN | Chief Product Strategy Officer | Buy | 7,500 | — | — |
| 2025-02-12 | KIEFFER, TARA LYNN | Chief Product Strategy Officer | Sale | 3,326 | $5.59 | $18592.34 |
| 2024-12-06 | ROTTINGHAUS, SCOTT T. | Chief Medical Officer | Sale | 866 | $8.06 | $6979.96 |
| 2024-12-06 | OR, YAT SUN | Chief Scientific Officer | Sale | 2,591 | $8.06 | $20883.46 |
| 2024-12-06 | MELLETT, PAUL J | Chief Fin. & Admin Officer | Sale | 2,591 | $8.06 | $20883.46 |
| 2024-12-06 | LUU, BRENDAN | Chief Business Officer | Sale | 2,283 | $8.06 | $18400.98 |
| 2024-12-06 | LULY, JAY R. | Director, President and CEO | Sale | 5,142 | $8.06 | $41444.52 |
| 2024-12-06 | KIEFFER, TARA LYNN | Chief Product Strategy Officer | Sale | 2,283 | $8.06 | $18400.98 |
| 2024-12-01 | OR, YAT SUN | Chief Scientific Officer | Sale | 1,595 | $8.60 | $13717.00 |
| 2024-12-01 | MELLETT, PAUL J | Chief Fin. & Admin Officer | Sale | 1,595 | $8.60 | $13717.00 |
| 2024-12-01 | LUU, BRENDAN | Chief Business Officer | Sale | 753 | $8.60 | $6475.80 |
| 2024-12-01 | LULY, JAY R. | Director, President and CEO | Sale | 3,829 | $8.60 | $32929.40 |
| 2024-12-01 | KIEFFER, TARA LYNN | Chief Product Strategy Officer | Sale | 753 | $8.60 | $6475.80 |
| 2024-11-27 | ROTTINGHAUS, SCOTT T. | Chief Medical Officer | Buy | 87,000 | — | — |
| 2024-11-27 | OR, YAT SUN | Chief Scientific Officer | Buy | 87,000 | — | — |
| 2024-11-27 | MELLETT, PAUL J | Chief Fin. & Admin Officer | Buy | 81,000 | — | — |
| 2024-11-27 | LUU, BRENDAN | Chief Business Officer | Buy | 75,000 | — | — |
| 2024-11-27 | LULY, JAY R. | Director, President and CEO | Buy | 250,000 | — | — |
| 2024-11-27 | KOWALSKY, MATTHEW PAUL | Chief Legal Officer | Buy | 75,000 | — | — |
| 2024-11-27 | KIEFFER, TARA LYNN | Chief Product Strategy Officer | Buy | 81,000 | — | — |
| 2024-08-08 | ROTTINGHAUS, SCOTT T. | Chief Medical Officer | Sale | 1,466 | $12.73 | $18662.18 |
| 2024-07-15 | ROTTINGHAUS, SCOTT T. | Chief Medical Officer | Sale | 5,375 | — | — |
| 2024-07-15 | ROTTINGHAUS, SCOTT T. | Chief Medical Officer | Sale | 5,375 | $17.08 | $91805.00 |
| 2024-07-12 | ROTTINGHAUS, SCOTT T. | Chief Medical Officer | Sale | 2,271 | $15.04 | $34155.84 |
| 2024-07-11 | ROTTINGHAUS, SCOTT T. | Chief Medical Officer | Sale | 4,299 | $15.07 | $64785.93 |
| 2024-06-17 | KIEFFER, TARA LYNN | Chief Product Strategy Officer | Sale | 7,266 | $12.33 | $89589.78 |
| 2024-04-29 | KOWALSKY, MATTHEW PAUL | Chief Legal Officer | Buy | 150,000 | — | — |
| 2024-03-06 | VANCE, TERRY | Director | Buy | 15,700 | — | — |
| 2024-03-06 | RUSSELL, LESLEY | Director | Buy | 15,700 | — | — |
| 2024-03-06 | PETERSON, KRISTINE | Director | Buy | 15,700 | — | — |
| 2024-03-06 | HATA, YUJIRO S | Director | Buy | 15,700 | — | — |
| 2024-03-06 | FOLETTA, MARK G | Director | Buy | 15,700 | — | — |
Frequently asked questions
Are ENTA insiders buying or selling?
Over the transactions on record, ENTA insiders have been net buyers, with about $1.22M in stock sold across 46 sales, against 1 open-market purchase.
Does insider selling at ENTA mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which ENTA insiders are selling the most?
Recent selling is concentrated in a few names. ROTTINGHAUS, SCOTT T. accounts for the largest share on record, with about $327439.30 sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.